Literature DB >> 22508031

Targeted therapies: Glioma--it's all in the site occupancy.

Lisa Hutchinson.   

Abstract

Year:  2012        PMID: 22508031     DOI: 10.1038/nrclinonc.2012.65

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  2 in total

1.  Kinetics of inhibitor cycling underlie therapeutic disparities between EGFR-driven lung and brain cancers.

Authors:  Krister J Barkovich; Sujatmi Hariono; Adam L Garske; Jie Zhang; Jimmy A Blair; Qi-Wen Fan; Kevan M Shokat; Theodore Nicolaides; William A Weiss
Journal:  Cancer Discov       Date:  2012-03-31       Impact factor: 39.397

2.  Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.

Authors:  Igor Vivanco; H Ian Robins; Daniel Rohle; Carl Campos; Christian Grommes; Phioanh Leia Nghiemphu; Sara Kubek; Barbara Oldrini; Milan G Chheda; Nicolas Yannuzzi; Hui Tao; Shaojun Zhu; Akio Iwanami; Daisuke Kuga; Julie Dang; Alicia Pedraza; Cameron W Brennan; Adriana Heguy; Linda M Liau; Frank Lieberman; W K Alfred Yung; Mark R Gilbert; David A Reardon; Jan Drappatz; Patrick Y Wen; Kathleen R Lamborn; Susan M Chang; Michael D Prados; Howard A Fine; Steve Horvath; Nian Wu; Andrew B Lassman; Lisa M DeAngelis; William H Yong; John G Kuhn; Paul S Mischel; Minesh P Mehta; Timothy F Cloughesy; Ingo K Mellinghoff
Journal:  Cancer Discov       Date:  2012-03-31       Impact factor: 39.397

  2 in total
  1 in total

Review 1.  Treating malignant glioma in Chinese patients: update on temozolomide.

Authors:  Liang Chang; Jun Su; Xiuzhi Jia; Huan Ren
Journal:  Onco Targets Ther       Date:  2014-02-12       Impact factor: 4.147

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.